🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

107 results for “Eli Lilly Co.” Clear

  1. 0.9% sodium chloride, Lepodisiran

    Eli Lilly Co.

    Atherosclerotic Cardiovascular Disease Elevated lp(a)

    phase 3 small molecule active

    1 trial

  2. ABEMACICLIB , FULVESTRANT

    Eli Lilly Co.

    Breast cancer

    phase 3 small molecule active

    1 trial

  3. ANASTROZOLE , PALBOCICLIB , TERSOLISIB, RIBOCICLIB , EXEMESTANE , FULVESTRANT , abemaciclib, TERSOLISIB, TERSOLISIB, TERSOLISIB, LETROZOLE , TERSOLISIB, to match Tersolisib (LY4064809), STX-478

    Eli Lilly Co.

    Neoplasm Metastasis, Breast Neoplasms

    phase 3 small molecule active

    1 trial

  4. BARICITINIB, ADALIMUMAB, ADALIMUMAB, Baricitinib, BARICITINIB, BARICITINIB

    Eli Lilly Co.

    Uveitis

    phase 3 small molecule active

    1 trial

  5. BARICITINIB, BARICITINIB, Placebo to match LY, Baricitinib

    Eli Lilly Co.

    Diabetes Mellitus, Type 1

    phase 3 small molecule active

    1 trial

  6. BARICITINIB, Baricitinib, BARICITINIB, BARICITINIB

    Eli Lilly Co.

    Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial

  7. BARICITINIB, Baricitinib, Placebo to match LY, BARICITINIB

    Eli Lilly Co.

    Diabetes Mellitus, Type 1

    phase 3 small molecule active

    1 trial

  8. BARICITINIB, TRIAMCINOLONE ACETONIDE, BARICITINIB, HYDROCORTISONE, Baricitinib, Placebo to match 4 mg tablet, BARICITINIB, HYDROCORTISONE, Hydrocutan Creme 1 %, Placebo to match 2mg tablet, Placebo to match 1mg tablet, Placebo to match 2mg/ml oral suspension

    Eli Lilly Co.

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  9. Baricitinib

    Eli Lilly Co.

    Covid19 Corona Virus Infection

    phase 3 small molecule active

    1 trial

  10. Cabozantinib, SELPERCATINIB, VANDETANIB, SELPERCATINIB, Cabozantinib, CABOZANTINIB

    Eli Lilly Co.

    RET-Mutant Medullary Thyroid Cancer

    phase 3 small molecule active

    1 trial

  11. DULAGLUTIDE , Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide

    Eli Lilly Co.

    Type 2 Diabetes Mellitus

    phase 3 small molecule active

    1 trial

  12. Donanemab, Florbetapir F18, Flortaucipir F18, Flortaucipir, FLORBETAPIR, SODIUM CHLORIDE PH. EUR.

    Eli Lilly Co.

    Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders

    phase 3 small molecule active

    1 trial

  13. EMPAGLIFLOZIN , DAPAGLIFLOZIN , INSULIN GLARGINE , Placebo to match LY3502970, METFORMIN

    Eli Lilly Co.

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  14. Eloralintide, Eloralintide, Eloralintide, Placebo to match LY, Eloralintide

    Eli Lilly Co.

    Overweight, Obesity, Sleep Apnea, Obstructive

    phase 3 small molecule active

    1 trial

  15. Eloralintide, Eloralintide, Placebo to match LY, Eloralintide, Eloralintide

    Eli Lilly Co.

    Overweight, Obesity

    phase 3 small molecule active

    1 trial

  16. Eloralintide, Placebo to match LY, Eloralintide, Eloralintide, Eloralintide

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  17. FULVESTRANT , EXEMESTANE , ABEMACICLIB

    Eli Lilly Co.

    Breast Cancer

    phase 3 small molecule active

    1 trial

  18. GEMCITABINE , CARBOPLATIN , MIRVETUXIMAB SORAVTANSINE, TOPOTECAN , LY4170156, BEVACIZUMAB , PACLITAXEL , DOXORUBICIN

    Eli Lilly Co.

    Fallopian Tube Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms, Neoplasm Metastasis

    phase 3 small molecule active

    1 trial

  19. Galcanezumab, Placebo to match LY2951742

    Eli Lilly Co.

    Migraine

    phase 3 small molecule active

    1 trial

  20. Galcanezumab, Placebo to match LY2951742

    Eli Lilly Co.

    Chronic Migraine

    phase 3 small molecule active

    1 trial

  21. Lebrikizumab, MOMETASONE , Placebo for Lebrikizumab

    Eli Lilly Co.

    Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

    phase 3 small molecule active

    1 trial

  22. Lebrikizumab, Placebo for Lebrikizumab, MOMETASONE

    Eli Lilly Co.

    Perennial Allergic Rhinitis (PAR)

    phase 3 small molecule active

    1 trial

  23. METFORMIN , DAPAGLIFLOZIN

    Eli Lilly Co.

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  24. Mirikizumab, Mirikizumab

    Eli Lilly Co.

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources